新诺迪斯克(Novo Nordisk)报告说,Q2利润猛增32%,但在竞争中,2025年的销售增长前景却更低。 Novo Nordisk reports a 32% jump in Q2 profit but lowers 2025 sales growth outlook amid competition.

丹麦制药巨头Novo Nordisk报告说,第二季度净利润增加了32%,达到265亿丹麦克朗(41亿美元),销售额增加18%,达到760亿丹麦克朗。 Danish pharmaceutical giant Novo Nordisk reported a 32% increase in second-quarter net profit, reaching DKK 26.5 billion ($4.1 billion), with sales up 18% to DKK 76 billion. 尽管销售额强劲,该公司面临Eli Lilly和林业发展局允许通用版本规则日益激烈的竞争,影响到收益。 Despite strong sales, the company faces growing competition from Eli Lilly and FDA rules allowing generic versions, impacting earnings. Novo Nordisk将其2025年的销售增长前景降至8-14%,低于以前的估计。 Novo Nordisk lowered its 2025 sales growth outlook to 8-14%, down from earlier estimates.